You are here: Industry Insights > NMPA

News List

APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clinical Trial in China for [18F]-APN-1607 Tau PET Imaging Tracer for Dementia prnasia
October 29, 2020
APRINOIA Therapeutics announced that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA's positron emission tomography (PET) imaging tracer, [18F]-APN-1607, targeting abnormal tau ...
Sihuan Pharmaceutical (0460.HK) receives approval for its exclusive medical aesthetic product Letybo (botulinum toxin), A blockbuster product in a hundred-billion size market prnasia
October 28, 2020
Sihuan Pharmaceutical Holdings Group Ltd. is pleased announce that "Type A Botulinum Toxin for Injection" (Letybo 100U), a product exclusively distributed by Sihuan Pharmaceutical, has officially received the marketing approval from the ...
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China prnasia
October 10, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company ...
Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors prnasia
September 22, 2020
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND) applications by the China National Medical Products Administration (NMPA) of its next-generation fully human ...
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency prnasia
August 04, 2020
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China National Medical Products Administration (NMPA) has accepted
Fosun Pharma Announces its Licensed COVID-19 Vaccine Product Receives Acceptance Notice of Clinical Trial Application by NMPA prnasia
July 14, 2020
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.
Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL) prnasia
July 08, 2020
In addition to China, Asieris has concurrently initiated this global multi-centered Phase III clinical trial in the United States, Germany, Romania, Hungary, Russia, and Ukraine.
Busy Month of Approvals: A Review of Oncology Drugs Approved in May in China and world market PharmaSources/Xiaobin
July 03, 2020
The first half of 2020 will pass soon. Although foreign countries are still under the shadow of the COVID-19 pandemic, China’s situation is gradually stabilizing and improving through the concerted efforts of all to fight the pandemic.
Summary of NMPA approved novel coronavirus 2019-nCoV test kits chinadaily
April 04, 2020
Since January 2020, following the principle of "unified command, early involvement, prompt review and approval based on science", the Center for Medical Device Evaluation has fulfilled its duty to review medical products that meet the requirements of "saf
Chinese ABRAXANE® supply expected to be disrupted europeanpharmaceuticalreview
March 27, 2020
The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page